Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allele

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Allele. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-005473-10 Sponsor Protocol Number: BEYOND Start Date*: 2021-11-24
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: BEZLOTOXUMAB YIELDED OUTCOMES BY ADDRESSING PERSONALIZED NEEDS IN CLOSTRIDIOIDES DIFFICILE INFECTION: THE BEYOND DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL
    Medical condition: Clostridioides difficile Infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004862 10085158 Clostridioides difficile infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001629-65 Sponsor Protocol Number: D7830C00004 Start Date*: 2023-03-13
    Sponsor Name:ASTRAZENECA AB
    Full Title: A Randomised, Double-blind, Placebo-Controlled, Multi-Center Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-Cirrhotic Non-Alcoholic Steatohepat...
    Medical condition: Non-cirrhotic non-alcoholic steatohepatitis with fibrosis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017148-15 Sponsor Protocol Number: CCOX189A2483 Start Date*: 2010-04-12
    Sponsor Name:NOVARTIS FARMA
    Full Title: A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126,...
    Medical condition: patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005497-38 Sponsor Protocol Number: RG_15-234 Start Date*: 2016-05-25
    Sponsor Name:University of Birmingham
    Full Title: Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms
    Medical condition: Myeloproliferative Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028576 Myeloproliferative disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-007416-15 Sponsor Protocol Number: VX08-770-102 Start Date*: 2009-08-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX 770 in Subjects with Cystic Fibrosis and the G551D Mutation
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000672-28 Sponsor Protocol Number: VX10-770-107 Start Date*: 2017-03-27
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FE...
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003009-31 Sponsor Protocol Number: HH007 Start Date*: 2022-12-23
    Sponsor Name:Zealand University Hospital, dept. of Haematology
    Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis
    Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001638-33 Sponsor Protocol Number: IKEM-CEM-01 Start Date*: 2012-10-10
    Sponsor Name:Institute for Clinical and Experimental Medicine
    Full Title: Cholesterol 7alpha-hydroxylase polymorphism as a predictor cholesterolemia responsiveness
    Medical condition: hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007479-26 Sponsor Protocol Number: VX08-770-103 Start Date*: 2009-08-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, 2 Part, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX 770 in Subjects Aged 6 to 11 Years with Cystic Fibr...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020546-96 Sponsor Protocol Number: VX10-770-106 Start Date*: 2010-10-08
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of VX-770 on Lung Clearance Index in Subjects with Cystic Fibrosis, the G551D Mutation, and FEV1 >90%...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002431-30 Sponsor Protocol Number: GT005-03 Start Date*: 2020-10-21
    Sponsor Name:Gyroscope Therapeutics
    Full Title: HORIZON: A Phase II, open-label, outcomes-assessor masked, multicentre, randomised,controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal inj...
    Medical condition: Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The prima...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075719 Atrophic age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) FR (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015176-10 Sponsor Protocol Number: BRD 09/6-C Start Date*: 2010-01-06
    Sponsor Name:CHU de Nantes
    Full Title: CLOFARABINE/ARA-C TREATMENT COMBINED WITH REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTEMYELOID LEUKEMIA IN PRIMARY TREATMENT FAILURE
    Medical condition: To improve the 2 year overall survival in patients with acute myeloid leukaemia (AML) in primary treatment failure
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003821-93 Sponsor Protocol Number: VX11-661-101 Start Date*: 2013-03-13
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Multicenter, Double Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subject...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005226-21 Sponsor Protocol Number: ARD12181 Start Date*: 2012-03-12
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis,...
    Medical condition: Hematopoietic neoplasm
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10018864 Haematopoietic neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) ES (Prematurely Ended) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002657-23 Sponsor Protocol Number: VX06-770-101 Start Date*: 2007-10-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects with Genotype G551D
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004838-25 Sponsor Protocol Number: VX14-661-109 Start Date*: 2015-05-20
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With ...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) IE (Completed) BE (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000588-99 Sponsor Protocol Number: BLU-285-2203 Start Date*: 2019-03-15
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indole...
    Medical condition: Indolent Systemic Mastocytosis (ISM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042949 Systemic mastocytosis PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056452 Indolent systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) DE (Ongoing) ES (Ongoing) NL (Ongoing) DK (Ongoing) IT (Ongoing) SE (Ongoing) FR (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005173-28 Sponsor Protocol Number: BLU-263-1201 Start Date*: 2021-09-06
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
    Medical condition: Indolent Systemic Mastocytosis (ISM) and monoclonal Mast Cell Activation Syndrome (mMCAS)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056452 Indolent systemic mastocytosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Ongoing) FR (Ongoing) ES (Ongoing) AT (Ongoing) NL (Ongoing) PT (Ongoing) IT (Ongoing) DK (Ongoing) SE (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004576-22 Sponsor Protocol Number: IRI28 Start Date*: 2017-07-14
    Sponsor Name:Catharina Hospital Eindhoven
    Full Title: SAFETY, FEASIBILITY AND COST-ANALYSIS OF UGT1A1 GENOTYPE-GUIDED DOSING OF IRINOTECAN
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002226-11 Sponsor Protocol Number: SIMaMCI Start Date*: 2008-10-07
    Sponsor Name:Charité - Unversitätsmedizin Berlin
    Full Title: Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients
    Medical condition: Amnestic mild cognitive impairment (MCI) denotes clinical conditions in the border zone between normal cognitive functioning and dementia. The definition of amnestic MCI by Petersen and his co-work...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA